What is William Blair’s Forecast for DexCom FY2025 Earnings?

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at William Blair decreased their FY2025 EPS estimates for DexCom in a report released on Friday, October 31st. William Blair analyst B. Vazquez now expects that the medical device company will post earnings per share of $2.05 for the year, down from their previous forecast of $2.06. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.66 EPS, Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.45 EPS, Q1 2027 earnings at $0.67 EPS, Q2 2027 earnings at $0.71 EPS, Q3 2027 earnings at $0.75 EPS and FY2027 earnings at $2.90 EPS.

Other equities analysts have also recently issued research reports about the stock. Royal Bank Of Canada reduced their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday. Cowen reaffirmed a “buy” rating on shares of DexCom in a research note on Friday, October 24th. Barclays boosted their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $91.65.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $58.22 on Monday. The company has a 50 day moving average of $70.94 and a 200 day moving average of $78.02. The stock has a market cap of $22.83 billion, a P/E ratio of 40.43, a P/E/G ratio of 1.43 and a beta of 1.47. DexCom has a 12 month low of $56.44 and a 12 month high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the company earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On DexCom

A number of hedge funds have recently made changes to their positions in the business. Intact Investment Management Inc. lifted its holdings in shares of DexCom by 102.9% in the 3rd quarter. Intact Investment Management Inc. now owns 33,890 shares of the medical device company’s stock worth $2,280,000 after acquiring an additional 17,190 shares during the last quarter. MBM Wealth Consultants LLC lifted its holdings in shares of DexCom by 4.1% in the 3rd quarter. MBM Wealth Consultants LLC now owns 9,228 shares of the medical device company’s stock worth $621,000 after acquiring an additional 361 shares during the last quarter. Sector Gamma AS lifted its holdings in shares of DexCom by 53.6% in the 3rd quarter. Sector Gamma AS now owns 76,821 shares of the medical device company’s stock worth $5,169,000 after acquiring an additional 26,821 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of DexCom by 29.8% in the 3rd quarter. CIBC Asset Management Inc now owns 156,185 shares of the medical device company’s stock worth $10,510,000 after acquiring an additional 35,824 shares during the last quarter. Finally, GDS Wealth Management lifted its holdings in shares of DexCom by 5.9% in the 3rd quarter. GDS Wealth Management now owns 200,452 shares of the medical device company’s stock worth $13,488,000 after acquiring an additional 11,134 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 5,383 shares of company stock valued at $434,274. Company insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.